Orthocell Ltd
ASX:OCC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.98
1.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
OCC
stock under the Base Case scenario is
0.33
AUD.
Compared to the current market price of 1.1 AUD,
Orthocell Ltd
is
Overvalued by 70%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Orthocell Ltd.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Orthocell’s lead regenerative platform, CelGro, faces an extended path to widespread adoption due to lingering questions around cost-effectiveness and a need for robust comparative data against established competitors’ regenerative products.
The company’s reliance on future regulatory milestones, particularly in key markets like the U.S. and Europe, adds considerable uncertainty to the near-term revenue outlook and heightens the risk of expensive delays if trials or approvals do not proceed as planned.
Orthocell’s relatively small scale and limited commercial infrastructure may hinder its ability to capture market share against larger, well-capitalized medtech and biotech firms, particularly if it requires aggressive marketing and sales efforts to win surgeon and hospital adoption.
CelGro’s potential to address multiple indications—nerve, bone, tendon, and soft tissue repair—positions Orthocell for significant long-term growth if positive clinical results continue and the platform gains broader reimbursement support.
Orthocell’s focused R&D strategy has produced early clinical successes, such as promising outcomes in dental and nerve regeneration, which could establish the company as a leader in the niche of collagen-based regenerative scaffolds, attracting licensing or acquisition interest from larger players.
The company’s methodical approach to collaboration, including partnerships with research institutions and medical specialists, sets a foundation for peer-reviewed evidence and strong surgeon buy-in, which could accelerate CelGro’s market acceptance and fuel international expansion.
Revenue & Expenses Breakdown
Orthocell Ltd
Balance Sheet Decomposition
Orthocell Ltd
| Current Assets | 31.8m |
| Cash & Short-Term Investments | 28.6m |
| Receivables | 1.8m |
| Other Current Assets | 1.4m |
| Non-Current Assets | 3.4m |
| PP&E | 2.3m |
| Intangibles | 1.1m |
| Other Non-Current Assets | -100 |
| Current Liabilities | 6.4m |
| Accounts Payable | 2.2m |
| Accrued Liabilities | 1.7m |
| Other Current Liabilities | 2.5m |
| Non-Current Liabilities | 14.3m |
| Long-Term Debt | 411.6k |
| Other Non-Current Liabilities | 13.9m |
Free Cash Flow Analysis
Orthocell Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Orthocell Ltd
|
Revenue
|
9.2m
AUD
|
|
Cost of Revenue
|
-2.7m
AUD
|
|
Gross Profit
|
6.5m
AUD
|
|
Operating Expenses
|
-18.2m
AUD
|
|
Operating Income
|
-11.8m
AUD
|
|
Other Expenses
|
3.2m
AUD
|
|
Net Income
|
-8.6m
AUD
|
OCC Profitability Score
Profitability Due Diligence
Orthocell Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Orthocell Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
OCC Solvency Score
Solvency Due Diligence
Orthocell Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.
Score
Orthocell Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OCC Price Targets Summary
Orthocell Ltd
According to Wall Street analysts, the average 1-year price target for
OCC
is 1.36 AUD
with a low forecast of 1.34 AUD and a high forecast of 1.4 AUD.
Dividends
Current shareholder yield for
OCC is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
OCC
stock under the Base Case scenario is
0.33
AUD.
Compared to the current market price of 1.1 AUD,
Orthocell Ltd
is
Overvalued by 70%.